# The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer

Source: https://onco.cc/trials/nct05628038/  
OnCo record `nct05628038` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of capecitabine, fluorouracil (5-FU), leucovorin (folinic acid), fOLFOX (5-FU, leucovorin, oxaliplatin) and other drugs in colorectal cancer, run by Fudan University, now recruiting.

## Summary

The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer is a phase 2, interventional study registered as NCT05628038 by Fudan University, with a registry enrolment figure of 93 participants, started 2022-11-30 and due to reach its primary completion in 2024-12-01. Interventions recorded: PD-1 antibody; Capecitabine; 5FU; folinic acid; Oxaliplatin; Irinotecan; Raltitrexed; Cetuximab; Bevacizumab; Radiation. Conditions listed: Recurrent Rectal Cancer. Primary outcome: Local objective response rate. Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: TORCH-R
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT05628038
- Phase: 2
- Setting: Hypofractionated Radiotherapy Combined With Toripalimab and Chemotherapy +/- Target Therapy for Locally Recurrent Rectal Cancer: a Single-arm, Two-cohort, Phase II Trial (TORCH-R)
- Sponsor: Fudan University
- Enrolled: 93

## Sources

- ClinicalTrials.gov NCT05628038: https://clinicaltrials.gov/study/NCT05628038

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [Platinum agents](https://onco.cc/technologies/platinum/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [Bevacizumab (glioblastoma use)](https://onco.cc/drugs/bevacizumab-glioma/), [Capecitabine](https://onco.cc/drugs/capecitabine/), [Cetuximab](https://onco.cc/drugs/cetuximab/), [Fluorouracil (5-FU)](https://onco.cc/drugs/fluorouracil/), [FOLFIRI (5-FU, leucovorin, irinotecan)](https://onco.cc/drugs/folfiri/), [FOLFOX (5-FU, leucovorin, oxaliplatin)](https://onco.cc/drugs/folfox/), [Leucovorin (folinic acid)](https://onco.cc/drugs/leucovorin/), [Raltitrexed](https://onco.cc/drugs/raltitrexed/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05628038.json